# OnCo record b-incentive-misalignment (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-incentive-misalignment/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-incentive-misalignment" ;
  schema:name "Incentives reward me-too drugs and marginal gains"@en ;
  schema:description "The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure."@en ;
  schema:url <https://onco.cc/bottlenecks/b-incentive-misalignment/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/d41573-022-00030-4>, <https://doi.org/10.1001/jamaoncol.2015.0373>, <https://doi.org/10.1016/S1470-2045(20)30139-X>, <https://arpa-h.gov/> ;
  onco:related <https://onco.cc/collections/fda-approvals/>, <https://onco.cc/collections/esmo-guidelines/>, <https://onco.cc/roadmaps/trop2-adc-roadmap/>, <https://onco.cc/ideas/idea-fund-public-option-generic-oncology/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/imatinib/> ;
  onco:institutions <https://onco.cc/institutions/esmo/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/terms/accelerated-approval/>, <https://onco.cc/terms/breakthrough-designation/>, <https://onco.cc/terms/standard-of-care/>, <https://onco.cc/terms/first-line/>, <https://onco.cc/terms/project-frontrunner/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/>, <https://onco.cc/key-papers/paper-vokinger-lancet-oncol/>, <https://onco.cc/key-papers/paper-mailankody-jama-oncol/> .